Viatris Inc (VTRS): Completion of Acquisition or Disposition of Assets
Viatris Inc (VTRS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Viatris Completes Acquisition of Pacira BioSciences PITTSBURGH – Nov. 17, 2026 – Viatris Inc. (“Viatris”) (Nasdaq: VTRS), a global healthcare company, today announced that it has completed its acquisition of Pacira BioSciences, Inc. (“Pacira”) (Nasdaq: PCRX), a leade
- Role
- acquirer
- Counterparty
- Pacira BioSciences, Inc.
- Price per share
- $36.50 per Share
- Consideration
- cash
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
The transaction is now consummated: tender offer expired Nov. 16, Viatris accepted validly tendered shares, Purchaser merged into Pacira, and Pacira will be delisted. Viatris expects the acquisition to contribute $90 million to $100 million of total revenues for the remainder of 2026.
Market read
Traders can update positioning now that the acquisition is closed and a near-term revenue contribution range is provided.
What to watch
Post-close performance will depend on commercialization of Pacira’s portfolio and whether cost synergies and earnings growth materialize as guided.
Background
Viatris announced the Pacira tender offer on Oct. 8, 2026 and this 8-K reports completion of the acquisition/disposition of assets.
Ticker impact
Viatris completed its Pacira acquisition, accepted tendered shares, and will delist Pacira after the merger closes.
Likely modest upside bias as the market prices the completed acquisition and the stated 2026 revenue contribution.
The filing confirms tender acceptance, merger completion, and provides a specific incremental revenue range for the remainder of 2026, which can affect near-term expectations.
Market effects
Reinforces consolidation in specialty pharma/pain management and may shift read-through expectations for non-opioid pain competitors.
Primarily US-listed healthcare M&A sentiment; limited direct regional spillover beyond US healthcare investors.
Global healthcare investors may re-rate US pain-management assets as deal execution risk declines.
Counterpoint
The revenue contribution range is only for the remainder of 2026, so the market may focus on longer-term integration and synergy realization rather than the close itself.
Key entities
- companyViatris Inc
Nasdaq-listed acquirer completing the Pacira tender offer and merger.
- companyPacira BioSciences, Inc.
Nasdaq-listed target being acquired and delisted after the merger closes.
- acquirer subsidiaryPeach Purchaser Sub Inc.
Wholly owned Viatris subsidiary that accepted tendered shares and merged into Pacira.


